S-1: Apogee Therapeutics Announces Proposed Public Offering of 6,000,000 Shares

Apogee Therapeutics plans to offer 6,000,000 shares of its common stock to fund clinical trials and research programs.

Summary

• Apogee Therapeutics is planning a public offering of 6,000,000 shares of its common stock.
• The company intends to use the net proceeds, along with existing resources, to fund clinical trials and manufacturing for its APG777 and APG808 programs, as well as preclinical studies and clinical trials for APG990 and APG222 programs.
• A portion of the proceeds will also be used for additional research and development activities, capital expenditures, working capital, and general corporate purposes.
• The underwriters have a 30-day option to purchase up to an additional 900,000 shares of common stock.
• The company estimates net proceeds from the offering to be approximately $325.9 million, or $374.9 million if the underwriters exercise their option in full, based on an assumed offering price of $58.33 per share.
• The company's common stock trades on The Nasdaq Global Market under the symbol APGE.
• Apogee Therapeutics is an emerging growth company and a smaller reporting company, which allows it to comply with certain reduced public company reporting requirements.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the company's plans for growth and development, as well as positive clinical trial data. However, it also acknowledges the risks associated with investing in a clinical stage biotechnology company.

Positives

• The offering will provide Apogee Therapeutics with substantial capital to advance its clinical programs.
• Positive interim Phase 1 data for APG777 supports its potential as a treatment for moderate-to-severe AD.
• The company plans to initiate a Phase 2 clinical trial for APG777 in AD in the first half of 2024, ahead of schedule.
• APG808 healthy volunteer clinical trial is expected to enter the clinic ahead of scheduled in the first half of 2024 following receipt of regulatory clearance in February 2024.
• The company's existing cash, cash equivalents and marketable securities, together with the net proceeds from this offering, are expected to fund operating expenses and capital expenditure requirements into the first quarter of 2028.

Negatives

• Investing in the company's common stock involves significant risks, as detailed in the Risk Factors section of the prospectus.
• The company has incurred significant losses since inception and expects to incur significant losses for the foreseeable future.
• The company is substantially dependent on the success of its two most advanced programs, APG777 and APG808.
• The company's approach to the discovery and development of its programs is unproven.
• Preclinical and clinical development involves a lengthy and expensive process with uncertain outcomes.

Risks

• The company is a clinical stage biotechnology company with a limited operating history.
• The company will require substantial additional capital to finance its operations in the future.
• The company faces competition from entities that have developed or may develop programs for the diseases addressed by its programs.
• The company relies on collaborations and licensing arrangements with third parties.
• The company currently relies, and plan to rely in the future, on third parties to conduct and support its preclinical studies and clinical trials.
• The company's ability to protect its patents and other proprietary rights is uncertain.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable.

Future Outlook

The company estimates that the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the first quarter of 2028. The company also may evaluate APG777 in expansion indications including initiating a Phase 2 trial in asthma in 2025.

Management Comments

• With our broad pipeline and depth of expertise, we believe we can deliver value and meaningful benefit to patients underserved by todays standard of care.

Industry Context

Apogee Therapeutics is focused on developing differentiated biologics for I&I indications, a competitive field with existing therapies that have limitations. The company aims to overcome these limitations through advanced antibody engineering to optimize half-life and other properties.

Comparison to Industry Standards

• APG777's potentially best-in-class PK profile, including a half-life of approximately 75 days, supports testing higher exposures of drug in induction to potentially achieve improved clinical responses; and testing of maintenance dosing of every three or six months, representing two to four injections per year compared to the current treatment paradigm of 13 to 26 injections per year.
• The APG777 Phase 2 induction regimen is designed to exceed lebrikizumab (an IL-13 inhibitor with an overlapping epitope with APG777) exposures by approximately 30 to 40% with potential for improved clinical outcomes and maintenance regimen is designed to equal lebrikizumabs exposures.
• At 52 weeks, exposures of APG777 dosed every three months are designed to exceed those of lebrikizumab and exposures of APG777 dosed every six months are designed to equal those of lebrikizumab.

Stakeholder Impact

• Shareholders: Potential for increased value through successful clinical development and commercialization.
• Employees: Continued employment and potential for career growth.
• Patients: Access to potentially improved treatments for atopic dermatitis, asthma, COPD, and related I&I indications.
• Suppliers: Continued business relationships and potential for increased demand.
• Creditors: Potential for increased financial stability and ability to repay debts.

Next Steps

• Initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024.
• Advance APG808 healthy volunteer clinical trial into the clinic ahead of scheduled in the first half of 2024.
• Nominate a candidate for APG990 in 2024 and initiate a Phase 1 trial in healthy volunteers in 2025.
• Provide more detailed updates on earlier pipeline programs and combination strategy in an R&D Day in the fourth quarter of 2024.

Key Dates

Keywords

Apogee Therapeutics, public offering, common stock, APG777, APG808, clinical trials, biotechnology, atopic dermatitis, COPD, asthma, biologics